From the Department of Pediatric Gastroenterology, Hasbro Children's Hospital, Brown University, Providence, RI.
the Department of Anesthesiology & Pain Medicine, University of Washington School of Medicine, Seattle, WA.
J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):793-798. doi: 10.1097/MPG.0000000000003771. Epub 2023 Mar 13.
Pain is the most common symptom of acute pancreatitis (AP), and opioids have been utilized as the cornerstone of treatment. Despite the adverse effects of opioids, data on effective analgesia in children with AP is lacking. We aimed to evaluate analgesia prescribing patterns in pediatric AP, identify factors associated with opioid administration, and test the associations between opioid administration and hospital length of stay (LOS).
This is a retrospective cohort study of pediatric AP hospitalizations in a single institution from 2010 to 2020. Opioid administration was calculated for the first 48 hours of admission (morphine milligram equivalent; MME48). Data on multimodal analgesia [defined as the administration of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs)] during hospitalization was captured.
The sample included 224 patients, mean age 12.0 years (standard deviation = 4.9) and 58.9% female. Median LOS was 4 days (interquartile range 2-9). Most patients (71.4%) were prescribed opioids, 77.7% acetaminophen, 40.2% NSAIDs, and 37.5% multimodal analgesia. Opioid administration decreased over the study period; in contrast, there was an increase in multimodal analgesia administration. Opioid administration did not differ by sex, age, biliary versus non-biliary etiology, or race/ethnicity. In a multivariate regression model, lower albumin values ( P < 0.01) and younger age ( P < 0.05) were significant predictors of increased LOS, while MME48 was not associated with increased LOS.
Opioids were commonly administered; only 37.5% of children were administered multimodal analgesia during their hospitalization for AP. Opioid administration was not associated with increased LOS. Prospective studies are needed to determine optimal pain management for pediatric AP.
疼痛是急性胰腺炎(AP)最常见的症状,阿片类药物一直被用作治疗的基石。尽管阿片类药物有不良反应,但缺乏关于 AP 患儿有效镇痛的数据。我们旨在评估儿科 AP 中的镇痛药物处方模式,确定与阿片类药物给药相关的因素,并检验阿片类药物给药与住院时间(LOS)之间的关联。
这是一项对单家医院 2010 年至 2020 年期间收治的儿科 AP 住院患者进行的回顾性队列研究。计算了入院后前 48 小时的阿片类药物给药量(吗啡毫克当量;MME48)。还记录了住院期间多模式镇痛(定义为给予对乙酰氨基酚和非甾体抗炎药(NSAIDs))的数据。
样本包括 224 名患者,平均年龄为 12.0 岁(标准差=4.9),58.9%为女性。中位 LOS 为 4 天(四分位距 2-9)。大多数患者(71.4%)开具了阿片类药物,77.7%开具了对乙酰氨基酚,40.2%开具了 NSAIDs,37.5%开具了多模式镇痛。在研究期间,阿片类药物的给药量减少;相反,多模式镇痛的给药量增加。阿片类药物的给药量在性别、年龄、胆源性与非胆源性病因或种族/民族方面没有差异。在多变量回归模型中,较低的白蛋白值(P<0.01)和较年轻的年龄(P<0.05)是 LOS 延长的显著预测因素,而 MME48 与 LOS 延长无关。
阿片类药物通常被给予;只有 37.5%的儿童在 AP 住院期间接受多模式镇痛。阿片类药物的给药与 LOS 延长无关。需要前瞻性研究来确定儿科 AP 的最佳疼痛管理。